Madrigal Pharmaceuticals (MDGL) Expected to Post Earnings on Thursday

Madrigal Pharmaceuticals (NASDAQ:MDGL) is expected to be posting its Q2 2026 results before the market opens on Thursday, July 30th. Analysts expect the company to post earnings of ($2.66) per share and revenue of $351.3880 million for the quarter. Interested persons can find conference call details on the company’s upcoming Q2 2026 earning results page for the latest details on the call scheduled for Thursday, July 30, 2026 at 8:00 AM ET.

Madrigal Pharmaceuticals (NASDAQ:MDGL) last announced its quarterly earnings results on Wednesday, May 6th. The biopharmaceutical company reported ($3.25) earnings per share for the quarter, topping analysts’ consensus estimates of ($3.61) by $0.36. The business had revenue of $311.34 million for the quarter, compared to analysts’ expectations of $301.05 million. Madrigal Pharmaceuticals had a negative return on equity of 50.15% and a negative net margin of 27.32%.The business’s quarterly revenue was up 126.8% on a year-over-year basis. During the same period in the prior year, the firm earned ($3.32) EPS. On average, analysts expect Madrigal Pharmaceuticals to post $-7 EPS for the current fiscal year and $9 EPS for the next fiscal year.

Madrigal Pharmaceuticals Stock Up 1.2%

Madrigal Pharmaceuticals stock opened at $551.25 on Tuesday. Madrigal Pharmaceuticals has a 52 week low of $286.44 and a 52 week high of $615.00. The company has a current ratio of 3.50, a quick ratio of 3.16 and a debt-to-equity ratio of 0.63. The stock has a market cap of $12.71 billion, a price-to-earnings ratio of -43.07 and a beta of -1.05. The company’s 50-day moving average price is $516.68 and its two-hundred day moving average price is $499.64.

Insider Transactions at Madrigal Pharmaceuticals

In other Madrigal Pharmaceuticals news, Director Richard S. Levy sold 5,682 shares of Madrigal Pharmaceuticals stock in a transaction on Friday, May 22nd. The shares were sold at an average price of $515.44, for a total transaction of $2,928,730.08. Following the completion of the transaction, the director directly owned 22,015 shares of the company’s stock, valued at $11,347,411.60. The trade was a 20.51% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, insider David Soergel sold 1,042 shares of Madrigal Pharmaceuticals stock in a transaction dated Monday, June 1st. The stock was sold at an average price of $495.74, for a total transaction of $516,561.08. Following the completion of the sale, the insider owned 10,033 shares of the company’s stock, valued at $4,973,759.42. This trade represents a 9.41% decrease in their position. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders have sold 7,568 shares of company stock valued at $3,880,711 in the last quarter. 17.60% of the stock is currently owned by corporate insiders.

Institutional Investors Weigh In On Madrigal Pharmaceuticals

Institutional investors and hedge funds have recently made changes to their positions in the business. Kemnay Advisory Services Inc. bought a new stake in shares of Madrigal Pharmaceuticals during the fourth quarter worth about $39,000. Quarry LP purchased a new position in Madrigal Pharmaceuticals in the third quarter valued at about $39,000. Johnson Financial Group Inc. purchased a new position in Madrigal Pharmaceuticals in the third quarter valued at approximately $50,000. Smartleaf Asset Management LLC grew its stake in shares of Madrigal Pharmaceuticals by 50.8% during the 4th quarter. Smartleaf Asset Management LLC now owns 187 shares of the biopharmaceutical company’s stock worth $109,000 after acquiring an additional 63 shares during the period. Finally, Kestra Investment Management LLC purchased a new position in shares of Madrigal Pharmaceuticals in the second quarter worth about $85,000. Institutional investors own 98.50% of the company’s stock.

Analysts Set New Price Targets

A number of equities analysts have recently weighed in on MDGL shares. Bank of America dropped their target price on Madrigal Pharmaceuticals from $550.00 to $542.00 and set a “neutral” rating on the stock in a report on Thursday, June 11th. HC Wainwright reissued a “buy” rating and set a $620.00 price objective on shares of Madrigal Pharmaceuticals in a report on Wednesday, May 6th. Wells Fargo & Company started coverage on Madrigal Pharmaceuticals in a research report on Monday. They set an “overweight” rating and a $685.00 price objective for the company. Truist Financial raised their price objective on Madrigal Pharmaceuticals from $640.00 to $709.00 and gave the stock a “buy” rating in a research report on Wednesday, May 13th. Finally, Piper Sandler reiterated an “overweight” rating on shares of Madrigal Pharmaceuticals in a research report on Wednesday, June 24th. One analyst has rated the stock with a Strong Buy rating, thirteen have given a Buy rating, three have assigned a Hold rating and one has assigned a Sell rating to the stock. According to data from MarketBeat.com, the company has a consensus rating of “Moderate Buy” and a consensus price target of $687.73.

About Madrigal Pharmaceuticals

Madrigal Pharmaceuticals, Inc is a clinical-stage biopharmaceutical company focused on the development of innovative therapies for cardiovascular, metabolic and liver diseases. The company’s pipeline centers on novel, liver-directed agents designed to address significant unmet medical needs, with an emphasis on nonalcoholic steatohepatitis (NASH) and related metabolic disorders.

The lead product candidate, resmetirom (MGL-3196), is an orally administered, selective thyroid hormone receptor-? agonist in Phase 3 development for the treatment of NASH.